Resveratrol (Circulation).

Pterostilbene is the dimethylated form of the same stilbene skeleton and acts on the same sirtuin and Nrf2 targets. Its methyl groups slow phase two conjugation, so it persists longer than resveratrol while hitting the same nodes.

Resveratrol is cleared quickly by sulfotransferase and UDP-glucuronosyltransferase in the gut wall and liver. Quercetin is a substrate and inhibitor of those same enzymes, so co-dosing leaves more unconjugated resveratrol in circulation.

Piperine inhibits intestinal UGT activity, the main route by which resveratrol is conjugated before it reaches the bloodstream. Less first-pass conjugation means more of the parent stilbene arrives intact.

Sirtuins consume NAD+ each catalytic cycle, and resveratrol acts as an allosteric modulator of SIRT1. NMN raises the NAD+ pool that the activated enzyme needs, so one supplies the fuel and the other the tuning.

NR is phosphorylated to NMN and onward to NAD+, the cofactor sirtuin deacetylation depends on. Resveratrol acts on the enzyme side of the same reaction.

Resveratrol increases endothelial nitric oxide synthase expression and activity. Citrulline converts to arginine, the substrate that enzyme uses, so one raises capacity and the other supplies the raw material.

Arginine is the nitrogen donor that endothelial nitric oxide synthase converts to nitric oxide. Resveratrol acts upstream on the expression and phosphorylation state of that enzyme.

Dietary nitrate reaches nitric oxide through the nitrate nitrite reduction route, which needs no oxygen or eNOS. Resveratrol works through the enzymatic route, so the two arrive at the same signalling molecule by separate paths.

Pine bark procyanidins also raise eNOS activity and reduce oxidative quenching of nitric oxide by superoxide. Paired with resveratrol the vessel wall gets both stilbene and procyanidin input on the same endothelial target.

Grape seed contributes oligomeric proanthocyanidins while resveratrol is a stilbene from the skin of the same fruit. The two classes act on overlapping endothelial and antioxidant targets and are commonly formulated together.

Curcumin and resveratrol are both heavily glucuronidated at the gut wall and both act on NF-kB and Nrf2 signalling. Co-presence loads the same conjugating enzymes and touches the same transcriptional nodes.

Resveratrol reduces platelet aggregation by acting on cyclooxygenase and thromboxane formation, and EPA displaces arachidonic acid from the same platelet pathway. Together they push normal clotting behaviour further in one direction than either does alone.

Ginkgolides antagonise platelet activating factor while resveratrol dampens thromboxane-driven aggregation. The two act at different receptors on the same platelet response, so their effects add.

Nattokinase has fibrinolytic activity on the fibrin side of clot formation while resveratrol acts on platelet aggregation. Combining them touches both arms of normal clot dynamics at once.

Garlic organosulfur compounds inhibit platelet aggregation and resveratrol does the same through a different mediator. Stacked together the effect on normal platelet behaviour is additive.

Ascorbate reduces phenoxyl radicals formed when a polyphenol donates a hydrogen atom, returning the polyphenol to its active form. That recycling relationship is standard redox chemistry for the phenol class rather than a resveratrol-specific trial finding. It describes antioxidant behaviour in solution and in plasma, which is a marker-level property.

Tocopherol works in the lipid phase and resveratrol partitions between lipid and aqueous phases, so the two cover different compartments of the same oxidative chain reaction. Both also carry mild platelet effects at higher intakes, which is worth flagging when they are stacked with fish oil. The interaction is chemical, not an outcome that has been measured for the pair.

Ubiquinol is the lipid-phase antioxidant of the inner mitochondrial membrane and an electron carrier in the respiratory chain, while resveratrol acts upstream on AMPK and SIRT1 signalling that governs mitochondrial biogenesis. Pairing them addresses the machinery and its protection from two directions. No human trial of the combination is cited here.

Dihydrolipoate regenerates ascorbate and glutathione, which in turn regenerate oxidised polyphenols, so lipoic acid sits two steps upstream of resveratrol in the antioxidant network. Both also converge on AMPK signalling. This is network chemistry described at the marker level.

Both compounds modify Keap1 or its signalling and increase Nrf2-driven transcription of antioxidant and phase II enzymes. Acting on one pathway from two chemistries can produce a larger transcriptional response than either alone in cell systems. Cell-level evidence, not human outcomes.

The glucoraphanin in sprout extract is converted by myrosinase or gut bacteria to sulforaphane, which shares Nrf2 signalling with resveratrol. The pairing is common in redox formulas. What is established is the pathway overlap, not a clinical result for the pair.

Colonic bacteria reduce resveratrol to dihydroresveratrol and further metabolites, and the individual metabolite pattern varies widely between people. Which organisms are present therefore changes what circulates after a dose. This is a metabolism finding and it does not by itself mean a probiotic increases any effect.

A fermentable fibre shifts the composition and activity of the colonic community that metabolises stilbenes. That can change the metabolite profile reaching the circulation in either direction. Inference from established microbial pharmacology, not a measured pairing.

Polyphenols with adjacent hydroxyl groups bind non-heme iron in the gut lumen and lower its uptake, which is the same chemistry behind the tea and iron interaction. Anyone taking an iron supplement for iron status has reason to separate the two doses by a couple of hours. This is a well-characterised absorption competition, not a speculative one.

Stilbenes and other polyphenols coordinate copper ions, and copper-polyphenol complexes can behave as pro-oxidants in vitro rather than antioxidants. The practical consequence is a binding interaction to be aware of when both appear in one formula. In vitro chemistry, with no human data cited.

Resveratrol and catechins are both heavily conjugated by intestinal UGT and SULT enzymes, and each inhibits those enzymes at achievable gut concentrations. Co-dosing can raise free levels of one or both, which is a pharmacokinetic effect rather than a bigger biological effect. It is also why stilbene bioavailability data vary so much between studies.

Silymarin flavonolignans inhibit UGT and sulfotransferase activity, the main clearance route for resveratrol. Stacking them changes exposure to the stilbene. Pharmacokinetics, and a reason to be deliberate about the stack rather than assume additivity.

Resveratrol is poorly water soluble and its absorption depends on dissolution and micelle formation. Taking it with a fat source, or formulating it in one, is standard practice for compounds in this solubility class. The absorption step is what improves; nothing about that alone predicts an effect.

Phospholipid complexes, sold as phytosomes, are the usual way a poorly soluble polyphenol is made to disperse and permeate better. Lecithin is the phospholipid used. It changes delivery, not the underlying pharmacology.

Magnesium contributes to normal vascular smooth muscle relaxation and endothelium-dependent tone, the same physiology resveratrol is studied against through nitric oxide availability. Two mild influences on the same regulated variable can add, which is a reason to monitor rather than a benefit claim. Anyone already managing blood pressure with medication should have that conversation with a clinician.

Taurine influences endothelial nitric oxide handling and calcium regulation in vascular tissue. It overlaps with the nitric oxide pathway resveratrol acts on through eNOS expression. The overlap is mechanistic and the human evidence for the pair is absent.

Menaquinone carboxylates matrix Gla protein, the endogenous inhibitor of calcium deposition in vascular tissue, which is a different lever on vascular health than the redox and nitric oxide routes resveratrol occupies. The two do not compete. Pathway complementarity only, no combination data.

Lycopene is a lipophilic carotenoid that quenches singlet oxygen inside lipoprotein particles, a compartment where a stilbene has limited reach. Coverage of different compartments is the argument for pairing carotenoids with polyphenols. Marker-level antioxidant chemistry.

Hesperidin and its aglycone hesperetin act on endothelial nitric oxide signalling and on vascular inflammatory markers, overlapping with resveratrol's studied mechanisms from a different chemical class. Citrus flavonoids and stilbenes are also handled by the same conjugation enzymes, so exposure can shift when they are combined. Mechanistic, with markers rather than outcomes.

Urolithin A promotes mitophagy, the clearance arm of mitochondrial quality control, while resveratrol acts on the biogenesis arm through AMPK and PGC-1 alpha signalling. Clearance and renewal are two halves of one cycle. This is a reasoned pairing from cell biology and nothing more.

Spermidine induces autophagy through acetyltransferase inhibition, a route independent of the sirtuin and AMPK signalling associated with resveratrol, and both converge on the same cellular housekeeping process. Cell and animal work supports the pathway overlap. No human combination evidence.

Both compounds activate AMPK signalling and both have been studied for effects on fasting glucose markers. Stacking two AMPK-active compounds can produce a larger effect on blood sugar than expected, which matters for anyone already using glucose-lowering medication. Flagged as an additive effect to watch, not as a benefit.

Melatonin is a direct radical scavenger with good tissue penetration and it also influences nocturnal vascular tone. It overlaps with resveratrol on the redox side while acting through its own receptors. Early, mechanism-level, and it carries melatonin's own sedative property.